Cargando…
A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
Autores principales: | Urba, Walter, Chmielowski, Bartosz, Loo, Deryk, Baughman, Jan, Chen, Francine, Moore, Paul, Bonvini, Ezio, Vasselli, James, Wigginton, Jon, Rizvi, Naiyer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646124/ http://dx.doi.org/10.1186/2051-1426-3-S2-P176 |
Ejemplares similares
-
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
por: Baughman, Jan, et al.
Publicado: (2015) -
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
por: Powderly, John, et al.
Publicado: (2015) -
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
por: Chmielowski, Bartosz
Publicado: (2013) -
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma
por: Hurwitz, Herbert, et al.
Publicado: (2014) -
A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
por: Uy, Geoffrey, et al.
Publicado: (2014)